The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach.
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Multiple myeloma (MM) Heavy/light chain (HLC) assay Hevylite® Diagnosis Prognosis Monitoring
Fecha
2021-10-30Referencia bibliográfica
Ríos-Tamayo, R.; Puig, N.; Algarín, M.; García de Veas Silva, J.L.; Barbosa, N.; Encinas, C.; Hernández, J.Á.; Alonso, R.; Campos, M.L.; Rodríguez, T.; et al. The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics 2021, 11, 2020. [https:// doi.org/10.3390/diagnostics11112020]
Resumen
Despite tremendous progress being made in recent years, multiple myeloma (MM) remains
a challenging disease. The laboratory plays a critical role in the overall management of patients. The
diagnosis, prognosis, clinical monitoring and evaluation of the response are key moments in the
clinical care process. Conventional laboratory methods have been and continue to be the basis of
laboratory testing in monoclonal gammopathies, along with the serum free light chain test. However,
more accurate methods are needed to achieve new and more stringent clinical goals. The heavy/light
chain assay is a relatively new test which can overcome some of the limitations of the conventional
methods for the evaluation of intact immunoglobulin MM patients. Here, we report an update of the
evidence accumulated in recent years on this method regarding its use in MM.